ISTILOS™ B. infantis

About ISTILOS^™ B. infantis

The probiotic strain ISTILOS^™ B. infantis was isolated from the intestine of a healthy infant.
It is safe for consumption, the species has a QPS (Qualified Presumption of Safety) status in Europe. The ISTILOS^™ B. infantis strain has been notified as GRAS (Generally Recognized as Safe), with "no questions" from the U.S. Food and Drug Administration (FDA) in March 2021 (GRN no. 950).
It has been used since the early 2000s as an ingredient in food and food supplements.
The benefits of this strain have been known for decades, supported by high-quality clinical studies.
In 2023, Bifidobacterium longum subsp. infantis, Bifin02^™* was trademarked with the commercial name ISTILOS^™ B. infantis.

Clinically demonstrated health benefits

As part of a three-strain blend investigated in clinical trials and pre-clinical studies, ISTILOS^™ B. infantis was shown to:

Seed and thrive in the infant gut¹
Produce metabolites that are known to be involved in the development of the immune system and support gut barrier function^1,2

Clinical studies involving ISTILOS^™ B. infantis

The probiotic strain ISTILOS^™ has been demonstrated to effectively colonize the infant gut in a recent clinical trial and produce metabolites known to help develop the immune system and support gut barrier function.^{1, 2}

In an open-label trial¹, 23 newborns received a three-strain blend containing ISTILOS^™ B. infantis, Bifidobacterium animalis subsp. lactis, BB-12^®, and L. rhamnosus LGG^® for 28 days. The ISTILOS^™ strain was detected in the stool of all the newborns in increasing quantities even after supplementation ceased, demonstrating that the probiotic strain ISTILOS^™ could seed and thrive in the gut of these infants.

Strict production requirements ensure the highest quality

In general, when delivering products intended for infant use Chr. Hansen has implemented the strictest of production processes. Chr. Hansen’s extra requirements include extended contaminant testing and stricter requirements regarding both environmental monitoring and cleaning before production to eliminate the risk of contamination.

ISTILOS^™, BB-12^® and TH-4^® are registered trademarks of Chr. Hansen A/S